Abstract
Since the discovery of ouabain as a cardiotonic steroid hormone present in higher mammals, research about it has progressed rapidly and several of its physiological and pharmacological effects have been described. Ouabain can behave as a stress hormone and adrenal cortex is its main source. Direct effects of ouabain are originated due to the binding to its receptor, the Na+/K+-ATPase, on target cells. This interaction can promote Na+ transport blockade or even activation of signaling transduction pathways (e.g., EGFR/Src-Ras-ERK pathway activation), independent of ion transport. Besides the well-known effect of ouabain on the cardiovascular system and blood pressure control, compelling evidence indicates that ouabain regulates a number of immune functions. Inflammation is a tightly coordinated immunological function that is also affected by ouabain. Indeed, this hormone can modulate many inflammatory events such as cell migration, vascular permeability, and cytokine production. Moreover, ouabain also interferes on neuroinflammation. However, it is not clear how ouabain controls these events. In this brief review, we summarize the updates of ouabain effect on several aspects of peripheral and central inflammation, bringing new insights into ouabain functions on the immune system.
Introduction
Although the cardiotonic steroid ouabain was originally identified as a plant secondary metabolite (e.g., from Strophantus gratus and Acokanthera ouabaio), it was later described as an endogenous mammalian substance (Hamlyn et al., 1991) such as other cardiotonic steroids (e.g., marinobufagenin and digoxin) (Bagrov et al., 2009). Ouabain was found in bovine adrenal gland (Laredo et al., 1994; Schneider et al., 1998), adrenal gland tumors (Blanco and Wallace, 2013), bovine hypothalamus (Tymiak et al., 1993), bovine hypophysis (Schoner, 2002), and human plasma (Hamlyn et al., 1991; Ferrandi et al., 1997). It is noteworthy that ouabain isolated from mammalian tissues and body fluids is structurally, biochemically, and immunologically indistinguishable to ouabain isolated from plants (Schoner, 2002).
Ouabain synthesis seems to occur in the zona glomerulosa and fasciculata of the adrenal gland cortex (Masugi et al., 1988; Laredo et al., 1995), using hydroxycholesterol, pregnenolone, and progesterone (Hamlyn et al., 1998; Schoner and Scheiner-Bobis, 2007) as precursors. Thereafter, ouabain is released into the circulation after stimulation by adrenocorticotropic hormone (Lewis et al., 2014), epinephrine (Schoner and Scheiner-Bobis, 2005), angiotensin II (Laredo et al., 1997), and α1-adrenergic receptor agonists (Schoner, 2002; Schoner and Scheiner-Bobis, 2007). In rats, the physiological role of ouabain is associated to vasculature tone control and natriuresis (Nesher et al., 2009).
Ouabain levels are increased in different conditions such as chronic renal insufficiency (Stella et al., 2008), chronic salt intake (Blanco and Wallace, 2013), congestive heart failure (Manunta et al., 2009, 2010), hypertension (Hauck and Frishman, 2012), pregnancy (Dvela-Levitt et al., 2015), and primary hyperaldosteronism (Rossi et al., 1995). This steroid is also associated with stress conditions, such as physical exercise (Antolovic et al., 2000; Bauer et al., 2005). In addition, high levels of ouabain are correlated with cortisol concentration (Berendes et al., 2003), which reinforces its role as a stress hormone.
Besides its role as a Na+/K+-ATPase (sodium pump) inhibitor (Lingrel, 2010), which is associated with cardiovascular effects (Hamlyn and Blaustein, 2013; Blaustein et al., 2016), ouabain, at low concentrations, triggers Na+/K+-ATPase-mediated signaling pathways (Xie and Askari, 2002; Xie and Cai, 2003). These relayed signals cascades include Src kinase, MAPK, and NF-κB activation, reactive oxygen species release and others (Saunders and Scheiner-Bobis, 2004; Aperia, 2007). Ouabain induces several biological regulatory effects, including cell proliferation, hypertrophy, apoptosis (Bagrov et al., 2009) resulting in different functional outcomes. Additionally, it has been demonstrated that ouabain modulates various immune system functions (Rodrigues-Mascarenhas et al., 2009), including inflammation. In this mini-review, we present the relationship between ouabain and inflammatory process.
Ouabain and immune system
The immune system is a highly specialized network of lymphoid organs, cells, humoral factors, and cytokines, which acts in order to maintain homeostasis (Parkin and Cohen, 2001). The relationship between ouabain and immune system was first studied when Quastel and Kaplan (1968) demonstrated that this steroid inhibits lymphocytes proliferation induced by the mitogen phytohaemagglutinin. This effect was later confirmed by several other reports that used different stimuli (e.g., anti-CD3 and IL-2) (Jensen et al., 1977; Dornand et al., 1986; Redondo et al., 1986; Olej et al., 1994; Brodie et al., 1995; Szamel et al., 1995). This phenomenon could be related to CD25 (Pires et al., 1997) and IL-2 reduced expression (Dornand et al., 1986; Szamel et al., 1995) induced by ouabain, since both molecules are required for lymphocyte proliferation. Moreover, ouabain reduces regulatory T cells absolute number in mice (Silva et al., 2015). It is noteworthy that CD25 is highly expressed and fundamental to regulatory T cells survival (Setiady et al., 2010). Besides that, it was also reported that ouabain induces cell death in stimulated lymphocytes (Olej et al., 1998; Esteves et al., 2005; Panayiotidis et al., 2010).
In thymocytes, T lymphocyte precursors, ouabain is able to modulate different events such as intracellular calcium concentration increase (Echevarria-Lima et al., 2003). It was also observed that this effect is related to CD69 increased expression, a molecule associated with cell activation, induced by ouabain (Rodrigues-Mascarenhas et al., 2003). Additionally, ouabain induces in vitro intracellular free radicals accumulation and thymocytes death (Smolyaninova et al., 2013). In vivo, ouabain synergizes with hydrocortisone increasing T lymphocyte precursors death by apoptosis (Rodrigues-Mascarenhas et al., 2006), which reinforces its role as a stress-related hormone. Moreover, ouabain reduced NFAT expression and P-p38 levels, after concanavalin A stimulation (Rodrigues-Mascarenhas et al., 2008, 2009). This later data support the fact that ouabain modulates cell signaling (Xie and Askari, 2002).
Ouabain is also able to modulate in vivo B lymphocytes dynamics, decreasing mature B cells in the bone marrow, spleen and peripheral blood (de Paiva et al., 2011), although IgG and IgM levels were not affected by ouabain. On the other hand, there was an increase in B lymphocytes of mesenteric lymph node, probably by CD62L reduced and CXCR5 increased expression (da Silva et al., 2015).
Despite ouabain effects on B and T lymphocytes, natural killer (NK) cells seem to be resistant to ouabain. In fact, ouabain did not affect NK cell cytotoxic activity, in neither the absence nor presence of stimulatory agents (de Moraes et al., 1989). However, ouabain inhibits lymphokine-activated killer (LAK) cell generation induced by IL-2 (Olej et al., 1994).
Many lymphocytes functions rely on antigen presenting cells (APCs), in which dendritic cells (DC) have a highlighted role together with macrophages (Steinman, 2012). The influence of ouabain on DC was also described. Nascimento et al. (2014) demonstrated that ouabain modulates dendritic cells markers and IL-12 production during activation by TNF-α. Additionally, ouabain affects monocyte/macrophage activation (Sowa and Przewłocki, 1997; Teixeira and Rumjanek, 2014). Indeed, ouabain reduces CD14 expression, a molecule involved in foreign antigens recognition, in human monocytes (Valente et al., 2009; Teixeira and Rumjanek, 2014). Moreover, ouabain inhibits a proinflammatory monocyte subset (mCD14+CD16+) appearance in vitro, which may indicate that this steroid also modulates the inflammatory response.
Ouabain as a modulator of inflammation
Inflammation is an immunological complex response that can be triggered by pathogen- and damage-associated molecular patterns and is able to restore tissue homeostasis (Medzhitov, 2010). Acute inflammatory process is mainly characterized by vascular (e.g., vasodilation and vascular permeability) and cellular (e.g., leukocytes migration) alterations, resulting in five cardinal (clinical) signs: redness, swelling, heat, pain, and disturbance of function. Uncontrolled or unresolved inflammation can lead to homeostatic imbalance and chronic diseases, including cardiovascular and neurodegenerative diseases (Scrivo et al., 2011). Besides immune system role in inflammation, other systems, such as endocrine and nervous system, can also regulate this physiological response (Padro and Sanders, 2014; Procaccini et al., 2014). In fact, many hormones are known to affect inflammation, such as glucocorticoids (Cain and Cidlowski, 2017), and ghrelin, a pituitary-derived hormone (Baatar et al., 2011). In the following topics, ouabain role in the inflammatory process will be discussed.
Ouabain and peripheral inflammation
Acute peripheral inflammation initiates after inflammatory signals recognition (e.g., infection and tissue injury) by resident cells, such as mast cells and macrophages. This recognition promotes mediators release (e.g., vasoactive amines and prostaglandins), which stimulates rapid effects on the vasculature, including vasodilation and fluid extravasation (i.e., increased vascular permeability; Medzhitov, 2008). One of the first reports associating ouabain and inflammation revealed that this steroid suppresses vascular permeability in the sheep skin and pleural cavity induced by the irritant agent turpentine (Lancaster and Vegad, 1967). Later, our group demonstrated that ouabain given intraperitoneally decreases zymosan-induced plasma extravasation in mice peritoneal cavity (Leite et al., 2015) and reduces the mouse paw edema stimulated by several phlogistic agents (de Vasconcelos et al., 2011). However, Gonçalves-de-Albuquerque et al. (2014) showed that intratracheal administration of ouabain induces lung edema formation in mice. It is important to consider that ouabain effect on lung edema must be related to Na+/K+-ATPase inhibition in alveolar cells (Gonçalves-de-Albuquerque et al., 2014), while ouabain effects demonstrated by our group may be associated with cell signaling mechanisms in immune cell (e.g., P-p38 and NF-κB activity inhibition; Mascarenhas et al., 2014; Leite et al., 2015).
Vasodilation and vascular permeability are events tune regulated by vasoactive amines. Histamine, which plays a critical role among these vasoactive molecules, is released by perivascular mast cells together with other mediators (e.g., newly synthesized cytokines and tryptases) during inflammation (Nathan, 2002). Different ouabain effects on histamine secretion by mast cells have been described. Okazaki et al. (1976) reported that ouabain inhibits antigen-induced histamine release on guinea-pig mast cells. On the other hand, several studies revealed that ouabain increased histamine secretion induced by different agents on rat mast cells (Frossard et al., 1983; Amellal et al., 1984; Knudsen et al., 1992; Lago et al., 2001), while no ouabain effect on human mast cells (Senol et al., 2007) and basophils (Magro, 1977) were reported. Different protocols and species variation in the ouabain sensitivity of Na+/K+-ATPase (Abeywardena et al., 1984; Herzig and Mohr, 1984; Wang et al., 2001) could explain this discrepant ouabain effects on mast cell degranulation.
Upon initiation of acute inflammation, circulating leukocytes are able to recognize molecules (e.g., selectins, integrins, and chemokines) on activated vascular endothelium and, after rolling and adhesion steps, they cross blood vessel barrier and reach inflamed tissue (Ley et al., 2007; Vestweber, 2015; Kourtzelis et al., 2017). Neutrophils are the first cells recruited to the injured site, followed by other inflammatory cells such as monocytes (Kolaczkowska and Kubes, 2013; Wang and Arase, 2014). These polymorphonuclear leukocytes are important not only to eliminate microorganisms but they also play a key role in inflammation resolution (Mayadas et al., 2014; Sugimoto et al., 2016). Moreover, neutrophils role in chronic inflammation has been described and they are pointed as a target to emerging therapeutic strategies (Soehnlein et al., 2017). Considering this, blocking neutrophil recruitment appears to be a crucial way to avoid inflammation maintenance.
Ward and Becker (1970) initially described ouabain inhibitory effect on rabbit neutrophil migration toward bacterial chemotactic factors in vitro. In agreement with this study, our group revealed that ouabain pretreatment reduces mice neutrophil migration induced by zymosan, a component of the cell wall of yeast Saccharomyces cerevisiae, (Leite et al., 2015) and by Leishmania amazonensis (Jacob et al., 2013). These data provide clear evidence that ouabain inhibits neutrophil recruitment induced by microbial agents. This ouabain effect was also demonstrated in peritoneal inflammation induced by mitogen concanavalin A (de Vasconcelos et al., 2011). Furthermore, in airway allergic inflammation model, ouabain has an anti-migratory effect (Galvão et al., 2017). Ray and Samanta (1997) have also demonstrated that ouabain impairs in vitro human neutrophil migration, by interfering with IL-8 receptor recycling. Additionally, other studies have demonstrated that ouabain also decreases lung cancer cells migration (Liu et al., 2013), possibly by reducing the expression of molecules related to cell adhesion (e.g., integrins and ICAM) (Takada et al., 2009; Ninsontia and Chanvorachote, 2014) and cell migration (e.g., Src, Akt, and FAK) (Pongrakhananon et al., 2013; Shin et al., 2015).
However, the inhibitory effect of ouabain on cell migration seems to depend on the presence of a previous inflammatory stimulus, since ouabain itself given by inhalation (Feng et al., 2011) or intratracheally (Gonçalves-de-Albuquerque et al., 2014) causes acute lung inflammation with increased neutrophil migration. This proinflammatory effect was followed by LTB4 and PGE2 high levels, both lipid mediators associated with cell migration. Moreover, it has been demonstrated that ouabain at high concentrations induces VCAM-1 expression (an adhesion molecule) in murine endothelial cells (Bereta et al., 1995). Na+/K+-ATPase inhibition may be, at least partially, responsible for this ouabain effect (Lacroix-Lamandé et al., 2012; Gonçalves-de-Albuquerque et al., 2014), but Na+/K+-ATPase-dependent activation of signaling cascades (e.g., ERK and p38 MAPK) cannot be ruled out (Bereta et al., 1995; Feng et al., 2011). Indeed, Leu et al. (1973) demonstrated that ouabain stimulates guinea-pig alveolar and peritoneal macrophages migration independent of the sodium pump.
A different pattern of cytokines is present since the inflammation onset until resolution phase. These soluble proteins are secreted by a variety of cells (e.g., immune e non-immune cells) and allow intercellular communication, mediating and regulating inflammatory process. An imbalance in proinflammatory (e.g., TNF-α) and anti-inflammatory (e.g., IL-10) cytokine production could entail inflammatory disorders (Tayal and Kalra, 2008; Sugimoto et al., 2016). Monocytes/macrophages are immune cells that act as a key source of cytokines because of their plasticity ability (i.e., change their pattern of cytokines and functions when exposed to different signals; Gordon and Taylor, 2005; Mantovani et al., 2014). It has been described that ouabain itself can stimulate human monocytes to secrete cytokines such as IL-1α, IL-1β, IL-6, and TNF-α (Foey et al., 1997; Matsumori et al., 1997, 2000; Teixeira and Rumjanek, 2014). Some different results are related to IL-6 and TNF-α production, which could be associated with individual variability of human donors. Indeed, critically ill patients with high levels of ouabain had higher serum concentrations of these proinflammatory cytokines and other inflammatory markers, such as C-reactive peptide and serum amyloid A, when compared to patients with low ouabain concentrations (Berendes et al., 2003). Interestingly, ouabain enhances interleukin-10 levels in human monocytes (Teixeira and Rumjanek, 2014). Recently, Kobayashi et al. (2017) demonstrated that ouabain effect on IL-1β release, in both macrophages and cardiac tissue, is related to NLRP3 inflammasome activation, which in turn is mediated through K+ efflux. It is noteworthy that in this study the authors used high doses of ouabain both in vitro and in vivo. This contrasts with other studies that show a reduction of a different pattern of cytokines, including IL-1β (Leite et al., 2015) with lower ouabain doses in presence of inflammatory stimulus (Jacob et al., 2013; Galvão et al., 2017).
Despite the well-established proinflammatory activities of some cytokines, such as TNF-α and IL-6, some studies have demonstrated their anti-inflammatory role (Liu et al., 1998; Zakharova and Ziegler, 2005; Masli and Turpie, 2008; Scheller et al., 2013). In this regard, use low concentrations of ouabain as cytokine immunoregulator could be useful in different clinical conditions. In fact, ouabain at low doses reverses sepsis-induced immunoparalysis by increase TNF-α, IFN-γ, and GM-CSF levels and improve mice survival (Dan et al., 2014).
Pain is another cardinal sign of inflammation, which is also modulated by ouabain. de Vasconcelos et al. (2011) demonstrated that intraperitoneal administration of ouabain reduces nociceptive behavior in mice model of inflammatory pain (i.e., acetic acid induced writhing test). This steroid also induces supraspinal antinociceptive activity, related to opioid mechanisms, since naloxone, an opioid antagonist, inhibits its effect. In addition, other studies revealed that ouabain intracerebroventricular (i.c.v.) (Calcutt et al., 1971) and intratechal (i.t.) (Zeng et al., 1999) injections at relative high doses (micrograms) produce central antinociception and potentiate morphine and clonidine central antinociceptive effect, mainly by enhancement of cholinergic transmission at the spinal cord level (Zeng et al., 1999, 2007). In contrast, it has also been shown that low doses (nanograms) of ouabain (i.c.v.) antagonize opioid receptor agonists (Masocha et al., 2003, 2016; Gonzalez et al., 2012) and that ouabain (i.t.) itself did not cause antinociception (Horvath et al., 2003). This pain modulation by ouabain, which depends on the dose and administration route used, suggests that it can modulate events in the central nervous system such as neuroinflammation.
Ouabain and neuroinflammation
Some studies have described ouabain role in the central nervous system (CNS). However, the effects of this steroid on neuroinflammation can be controversial. In a study with rat hippocampus, ouabain anti-inflammatory effect against neuroinflammation induced by LPS was observed. Acute intraperitoneal pre-treatment with this steroid reduced iNOS and IL-1β mRNA levels. In addition, ouabain also reduced p65 subunit NF-κB translocation and IκB degradation, both mechanisms important to inflammatory process (Kinoshita et al., 2014). However, when ouabain is administrated by intrahippocampal route in a concentration that does not inhibit Na+/K+-ATPase, it induces activation of NF-κB and increases iNOS and TNF-α mRNA levels (Kawamoto et al., 2012). As well as in peripheral inflammation, the anti-inflammatory effect of ouabain on hippocampus was only observed after an inflammatory stimulus. This could explain the different effects regarding NF-κB activation. Additionally, another study demonstrated the ability of ouabain to restore the lipid composition of rat hippocampal membranes in neuroinflammation induced by LPS (Garcia et al., 2015).
In rat cerebellar cell culture, ouabain at high concentrations induced NF-κB activation and consequent TNF-α and IL-1β cytokines increase through NMDA-Src-Ras pathway in absence of inflammatory stimulus (de Sá Lima et al., 2013). However, ouabain decreases IL-1β release in LPS-stimulated astrocytes (Forshammar et al., 2011). In spite of that, ouabain did not modulate IL-1β release in LPS-stimulated microglia, while increased TNF-α release at low concentration (Forshammar et al., 2013). Therefore, ouabain role in cytokine production at CNS level depends on cell type and concentration used. Besides that, ouabain effects on CNS could be associated with its role in bipolar and depressive disorders (Goldstein et al., 2006; Tonin et al., 2014). The interaction between neuroinflammation and cardiac steroids is more substantially detailed by Orellana et al. (2016).
Conclusions and perspectives
In summary, compelling evidence indicates that ouabain has a pro- and anti-inflammatory effects (Figure 1), which mainly depends on its concentration and functional state of cells (i.e., absence or presence of inflammatory stimulus), corroborating other ouabain effects on the immune system. However, to the best of our knowledge, studies relating ouabain and chronic inflammation are missing. In addition, more details about ouabain mechanism of action are necessary. Lastly, ouabain effects on the inflammatory process could be better explored in order to establish possible strategies for pharmacological treatment of immune dysregulation/inflammatory diseases.
Figure 1
Some cellular and molecular events modulated by ouabain on inflammatory process. Dual (pro- and anti-inflammatory) ouabain effects on the inflammation depend on some conditions such as ouabain concentration, cell type, and even functional state. This steroid hormone can modulate some cell signaling pathways due to Na+/K+-pump binding, which not necessarily means pump inhibition. (+) activation, (–) inhibition, ↑ increase, ↓ decrease.
Statements
Author contributions
Conceived and designed the manuscript: SR-M and LC-S. Wrote the manuscript: LC-S, AAA, DC, ÉAL, JG, JMS-N, and JFS. Final version: SR-M.
Acknowledgments
LC-S and JG are supported by Ph.D. fellowship from “Conselho Nacional de Desenvolvimento Científico e Tecnológico (CNPq).” DC, ÉAL, JMS-N, and JFS are supported by fellowship from “Coordenação de Aperfeiçoamento de Pessoal de Nível Superior” (CAPES).
Conflict of interest
The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
References
1
AbeywardenaM. Y.McMurchieE. J.RussellG. R.CharnockJ. S. (1984). Species variation in the ouabain sensitivity of cardiac Na+/K+-ATPase. A possible role for membrane lipids. Biochem. Pharmacol.33, 3649–3654. 10.1016/0006-2952(84)90152-7
2
AmellalM.BinckM.FrossardN.IlienB.LandryY. (1984). Sodium-potassium ATPase inhibition potentiates compound 48/80-induced histamine secretion from mast cells. Br. J. Pharmacol.82, 423–430. 10.1111/j.1476-5381.1984.tb10777.x
3
AntolovicR.BauerN.MohadjeraniM.KostH.NeuH.KirchU.et al. (2000). Endogenous ouabain and its binding globulin: effects of physical exercise and study on the globulin's tissue distribution. Hypertens. Res. 23, S93–S98. 10.1291/hypres.23.Supplement_S93
4
AperiaA. (2007). New roles for an old enzyme: Na,K-ATPase emerges as an interesting drug target. J. Intern. Med.261, 44–52. 10.1111/j.1365-2796.2006.01745.x
5
BaatarD.PatelK.TaubD. D. (2011). The effects of ghrelin on inflammation and the immune system. Mol. Cell. Endocrinol.340, 44–58. 10.1016/j.mce.2011.04.019
6
BagrovA. Y.ShapiroJ. I.FedorovaO. V. (2009). Endogenous cardiotonic steroids: physiology, pharmacology, and novel therapeutic targets. Pharmacol. Rev.61, 9–38. 10.1124/pr.108.000711
7
BauerN.Müller-EhmsenJ.KrämerU.HambarchianN.ZobelC.SchwingerR. H.et al. (2005). Ouabain-like compound changes rapidly on physical exercise in humans and dogs: effects of beta-blockade and angiotensin-converting enzyme inhibition. Hypertension45, 1024–1028. 10.1161/01.HYP.0000165024.47728.f7
8
BerendesE.CullenP.Van AkenH.ZidekW.ErrenM.HübschenM.et al. (2003). Endogenous glycosides in critically ill patients. Crit. Care Med.31, 1331–1337. 10.1097/01.CCM.0000059721.57219.C3
9
BeretaJ.CohenM. C.BeretaM. (1995). Stimulatory effect of ouabain on VCAM-1 and iNOS expression in murine endothelial cells: involvement of NF-κB. FEBS Lett.377, 21–25. 10.1016/0014-5793(95)01301-6
10
BlancoG.WallaceD. P. (2013). Novel role of ouabain as a cystogenic factor in autosomal dominant polycystic kidney disease. Am. J. Physiol. Renal Physiol.305, F797–F812. 10.1152/ajprenal.00248.2013
11
BlausteinM. P.ChenL.HamlynJ. M.LeenenF. H.LingrelJ. B.WierW. G.et al. (2016). Pivotal role of α2 Na+ pumps and their high affinity ouabain binding site in cardiovascular health and disease. J. Physiol.594, 6079–6103. 10.1113/JP272419
12
BrodieC.TordaiA.SalogaJ.DomenicoJ.GelfandE. W. (1995). Ouabain induces inhibition of the progression phase in human T-cell proliferation. J. Cell. Physiol.165, 246–253. 10.1002/jcp.1041650205
13
CainD. W.CidlowskiJ. A. (2017). Immune regulation by glucocorticoids. Nat. Rev. Immunol.17, 233–247. 10.1038/nri.2017.1
14
CalcuttC. R.DoggettN. S.SpencerP. S. (1971). Modification of the anti-nociceptive activity of morphine by centrally administered ouabain and dopamine. Psychopharmacologia21, 111–117. 10.1007/BF00572268
15
da SilvaJ. M.das Neves AzevedoA.dos Santos BarbosaR. P.ViannaT. A.FittipaldiJ.TeixeiraM. P.et al. (2015). Dynamics of murine B lymphocytes is modulated by in vivo treatment with steroid ouabain. Immunobiology221, 368–376. 10.1016/j.imbio.2015.09.020
16
DanC.JinjunB.Zi-ChunH.LinM.WeiC.XuZ.et al. (2014). Modulation of TNF-α mRNA stability by human antigen R and miR181s in sepsis-induced immunoparalysis. EMBO Mol. Med.7, 140–157. 10.15252/emmm.201404797
17
de MoraesV. L.OlejB.de la RocqueL.RumjanekV. M. (1989). Lack of sensitivity to ouabain in natural killer activity. FASEB J.3, 2425–2429.
18
de PaivaL. S.CostaK. M.CantoF. B.CabralV. R.FucsR.NobregaA.et al. (2011). Modulation of mature B cells in mice following treatment with ouabain. Immunobiology216, 1038–1043. 10.1016/j.imbio.2011.03.002
19
de Sá LimaL.KawamotoE. M.MunhozC. D.KinoshitaP. F.OrellanaA. M.CuriR.et al. (2013). Ouabain activates NFκB through an NMDA signaling pathway in cultured cerebellar cells. Neuropharmacology73, 327–336. 10.1016/j.neuropharm.2013.06.006
20
de VasconcelosD. I.LeiteJ. A.CarneiroL. T.PiuvezamM. R.de LimaM. R.de MoraisL. C.et al. (2011). Anti-inflammatory and antinociceptive activity of ouabain in mice. Mediat. Inflamm.2011:912925. 10.1155/2011/912925
21
DornandJ.FaveroJ.BonnafousJ. C.ManiJ. C. (1986). Mechanism whereby ouabain inhibits human T lymphocyte activation: effect on the interleukin 2 pathway. Immunobiology171, 436–450.
22
Dvela-LevittM.Cohen-Ben AmiH.RosenH.OrnoyA.Hochner-CelnikierD.GranatM.et al. (2015). Reduction in maternal circulating ouabain impairs offspring growth and kidney development. J. Am. Soc. Nephrol. 26, 1103–1114. 10.1681/ASN.2014020130
23
Echevarria-LimaJ.de AraújoE. G.de MeisL.RumjanekV. M. (2003). Ca2+ mobilization induced by ouabain in thymocytes involves intracellular and extracellular Ca2+ pools. Hypertension41, 1386–1392. 10.1161/01.HYP.0000072801.90600.C2
24
EstevesM. B.Marques-SantosL. F.Affonso-MitidieriO. R.RumjanekV. M. (2005). Ouabain exacerbates activation-induced cell death in human peripheral blood. An. Acad. Bras. Cienc.77, 281–292. 10.1590/S0001-37652005000200008
25
FengS.ChenW.CaoD.BianJ.GongF. Y.ChengW.et al. (2011). Involvement of Na(+), K (+)-ATPase and its inhibitors in HuR-mediated cytokine mRNA stabilization in lung epithelial cells. Cell Mol Life Sci.68, 109–124. 10.1007/s00018-010-0444-1
26
FerrandiM.ManuntaP.BalzanS.HamlynJ. M.BianchiG.FerrariP. (1997). Ouabain-like factor quantification in mammalian tissues and plasma: comparison of two independent assays. Hypertension30, 886–896. 10.1161/01.HYP.30.4.886
27
FoeyA. D.CrawfordA.HallN. D. (1997). Modulation of cytokine production by human mononuclear cells following impairment of Na,K-ATPase activity. Biochim. Biophys. Acta1355, 43–49. 10.1016/S0167-4889(96)00116-4
28
ForshammarJ.BlockL.LundborgC.BiberB.HanssonE. (2011). Naloxone and ouabain in ultralow concentrations restore Na+/K+-ATPase and cytoskeleton in lipopolysaccharide-treated astrocytes. J. Biol. Chem.286, 31586–31597. 10.1074/jbc.M111.247767
29
ForshammarJ.JörnebergP.BjörklundU.WesterlundA.LundborgC.BiberB.et al. (2013). Anti-inflammatory substances can influence some glial cell types but not others. Brain Res.1539, 34–40. 10.1016/j.brainres.2013.09.052
30
FrossardN.AmellalM.LandryY. (1983). Sodium-potassium ATPase, calcium, and immunological histamine release. Biochem. Pharmacol.32, 3259–3262. 10.1016/0006-2952(83)90215-0
31
GalvãoJ. G. F. M.Cavalcante-SilvaL. H. A.CarvalhoD. C. M.FerreiraL. K. D. P.MonteiroT. M.AlvesA. F.et al. (2017). Ouabain attenuates ovalbumin-induced airway inflammation. Inflamm. Res.66, 1117–1130. 10.1007/s00011-017-1092-9
32
GarciaI. J.KinoshitaP. F.ScavoneC.MignacoJ. A.BarbosaL. A.Santos HdeL. (2015). Ouabain modulates the lipid composition of hippocampal plasma membranes from rats with LPS-induced neuroinflammation. J. Membr. Biol. 248, 1191–1198. 10.1007/s00232-015-9840-7
33
GoldsteinI.LevyT.GaliliD.OvadiaH.YirmiyaR.RosenH.et al. (2006). Involvement of Na(+), K(+)-ATPase and endogenous digitalis-like compounds in depressive disorders. Biol. Psychiatry60, 491–499. 10.1016/j.biopsych.2005.12.021
34
Gonçalves-de-AlbuquerqueC. F.BurthP.SilvaA. R.de MoraesI. M.OliveiraF. M.SantelliR. E.et al. (2014). Murine lung injury caused by Leptospira interrogans glycolipoprotein, a specific Na/K-ATPase inhibitor. Respir. Res.15:93. 10.1186/s12931-014-0093-2
35
GonzalezL. G.MasochaW.Sánchez-FernándezC.AgilA.OcañaM.Del PozoE.et al. (2012). Changes in morphine-induced activation of cerebral Na(+),K(+)-ATPase during morphine tolerance: biochemical and behavioral consequences. Biochem. Pharmacol.83, 1572–1581. 10.1016/j.bcp.2012.02.023
36
GordonS.TaylorP. R. (2005). Monocyte and macrophage heterogeneity. Nat. Rev. Immunol.5, 953–964. 10.1038/nri1733
37
HamlynJ. M.BlausteinM. P. (2013). Salt sensitivity, endogenous ouabain and hypertension. Curr. Opin. Nephrol. Hypertens.22, 51–58. 10.1097/MNH.0b013e32835b36ec
38
HamlynJ. M.BlausteinM. P.BovaS.DuCharmeD. W.HarrisD. W.MandelF.et al. (1991). Identification and characterization of a ouabain-like compound from human plasma. Proc. Natl. Acad. Sci. U.S.A.88, 6259–6263. 10.1073/pnas.88.14.6259
39
HamlynJ. M.LuZ. R.ManuntaP.LudensJ. H.KimuraK.ShahJ. R.et al. (1998). Observations on the nature, biosynthesis, secretion and significance of endogenous ouabain. Clin. Exp. Hypertens. 20, 523–533. 10.3109/10641969809053230
40
HauckC.FrishmanW. H. (2012). Systemic hypertension: the roles of salt, vascular Na/K ATPase and the endogenous glycosides, ouabain and marinobufagenin. Cardiol. Rev.20, 130–138. 10.1097/CRD.0b013e31823c835c
41
HerzigS.MohrK. (1984). Action of ouabain on rat heart: comparison with its effect on guinea-pig heart. Br. J. Pharmacol.82, 135–142. 10.1111/j.1476-5381.1984.tb16450.x
42
HorvathG.AgilA.JooG.DobosI.BenedekG.BaeyensJ. M. (2003). Evaluation of endomorphin-1 on the activity of Na(+),K(+)-ATPase using in vitro and in vivo studies. Eur. J. Pharmacol.458, 291–297. 10.1016/S0014-2999(02)02813-3
43
JacobP. L.LeiteJ. A.AlvesA. K.RodriguesY. K.AmorimF. M.NérisP. L.et al. (2013). Immunomodulatory activity of ouabain in Leishmania leishmania amazonensis-infected Swiss mice. Parasitol. Res.112, 1313–1321. 10.1007/s00436-012-3146-9
44
JensenP.WingerL.RasmussenH.NowellP. (1977). The mitogenic effect of A23187 in human peripheral lymphocytes. Biochim. Biophys. Acta496, 374–383. 10.1016/0304-4165(77)90320-8
45
KawamotoE. M.LimaL. S.MunhozC. D.YshiiL. M.KinoshitaP. F.AmaraF. G.et al. (2012). Influence of N-methyl-D-aspartate receptors on ouabain activation of nuclear factor-kappaB in the rat hippocampus. J. Neurosci. Res.90, 213–228. 10.1002/jnr.22745
46
KinoshitaP. F.YshiiL. M.VasconcelosA. R.OrellanaA. M.Lima LdeS.DavelA. P.et al. (2014). Signaling function of Na, K-ATPase induced by ouabain against LPS as an inflammation model in hippocampus. J. Neuroinflamm.11:218. 10.1186/s12974-014-0218-z
47
KnudsenT.BertelsenH.JohansenT. (1992). Ouabain enhancement of compound 48/80 induced histamine secretion from rat peritoneal mast cells: dependence on extracellular sodium. Pharmacol. Toxicol.70, 412–418. 10.1111/j.1600-0773.1992.tb00499.x
48
KobayashiM.Usui-KawanishiF.KarasawaT.KimuraH.WatanabeS.MiseN.et al. (2017). The cardiac glycoside ouabain activates NLRP3 inflammasomes and promotes cardiac inflammation and dysfunction. PLoS ONE12:e0176676. 10.1371/journal.pone.0176676
49
KolaczkowskaE.KubesP. (2013). Neutrophil recruitment and function in health and inflammation. Nat. Rev. Immunol.13, 159–175. 10.1038/nri3399
50
KourtzelisI.MitroulisI.von RenesseJ.HajishengallisG.ChavakisT. (2017). From leukocyte recruitment to resolution of inflammation: the cardinal role of integrins. J. Leukoc. Biol.102, 677–683. 10.1189/jlb.3MR0117-024R
51
Lacroix-LamandéS.d'AndonM. F.MichelE.RatetG.PhilpottD. J.GirardinS. E.et al. (2012). Downregulation of the Na/K-ATPase pump by leptospiral glycolipoprotein activates the NLRP3 inflammasome. J. Immunol.188, 2805–2814. 10.4049/jimmunol.1101987
52
LagoJ.AlfonsoA.VieytesM. R.BotanaL. M. (2001). Ouabain-induced enhancement of rat mast cells response. Modulation by protein phosphorylation and intracellular pH. Cell Signal.13, 515–524. 10.1016/S0898-6568(01)00169-3
53
LancasterM. C.VegadJ. L. (1967). Suppression of the early inflammatory response in the sheep by strophanthin G. Nature213, 840–884. 10.1038/213840b0
54
LaredoJ.HamiltonB. P.HamlynJ. M. (1994). Ouabain is secreted by bovine adrenocortical cells. Endocrinology135, 794–797. 10.1210/endo.135.2.8033829
55
LaredoJ.HamiltonB. P.HamlynJ. M. (1995). Secretion of endogenous ouabain from bovine adrenocortical cells: role of the zonaglomerulosa and zonafasciculata. Biochem. Biophys. Res. Commun.212, 487–493. 10.1006/bbrc.1995.1996
56
LaredoJ.ShahJ. R.LuZ. R.HamiltonB. P.HamlynJ. M. (1997). Angiotensin II stimulates secretion of endogenous ouabain from bovine adrenocortical cells via angiotensin type 2 receptors. Hypertension29, 401–407. 10.1161/01.HYP.29.1.401
57
LeiteJ. A.AlvesA. K.GalvãoJ. G.TeixeiraM. P.Cavalcante-SilvaL. H.ScavoneC.et al. (2015). Ouabain modulates zymosan-induced peritonitis in mice. Med. Inflamm.2015:265798. 10.1155/2015/265798
58
LeuR. W.EddlestonA. W.GoodR. A.HaddenJ. W. (1973). Paradoxical effects of ouabain on the migration of peritoneal and alveolar macrophages. Exp. Cell Res.76, 458–461. 10.1016/0014-4827(73)90403-5
59
LewisL. K.YandleT. G.HiltonP. J.JensenB. P.BeggE. J.NichollsM. G. (2014). Endogenous ouabain is not ouabain. Hypertension64, 680–683. 10.1161/HYPERTENSIONAHA.114.03919
60
LeyK.LaudannaC.CybulskyM. I.NoursharghS. (2007). Getting to the site of inflammation: the leukocyte adhesion cascade updated. Nat. Rev. Immunol.7, 678–689. 10.1038/nri2156
61
LingrelJ. B. (2010). The physiological significance of the cardiotonic steroid/ouabain-binding site of the Na,K-ATPase. Annu. Rev. Physiol.72, 395–412. 10.1146/annurev-physiol-021909-135725
62
LiuJ.MarinoM. W.WongG.GrailD.DunnA.BettadapuraJ.et al. (1998). TNF is a potent anti-inflammatory cytokine in autoimmune-mediated demyelination. Nat. Med.4, 78–83. 10.1038/nm0198-078
63
LiuN.LiY.SuS.WangN.WangH.LiJ. (2013). Inhibition of cell migration by ouabain in the A549 human lung cancer cell line. Oncol. Lett.6, 475–479. 10.3892/ol.2013.1406
64
MagroA. M. (1977). Blocking of histamine release from human basophils in vitro by the ATPase inhibitor, ethacrynic acid. Clin. Exp. Immunol.29, 436–441.
65
MantovaniA.VecchiA.AllavenaP. (2014). Pharmacological modulation of monocytes and macrophages. Curr. Opin. Pharmacol.17, 38–44. 10.1016/j.coph.2014.07.004
66
ManuntaP.FerrandiM.BianchiG.HamlynJ. M. (2009). Endogenous ouabain in cardiovascular function and disease. J. Hypertens. 27, 9–18. 10.1097/HJH.0b013e32831cf2c6
67
ManuntaP.MessaggioE.CasamassimaN.GattiG.CarpiniS. D.ZagatoL.et al. (2010). Endogenous ouabain in renal Na+ handling and related diseases. Biochim. Biophys. Acta1802, 1214–1218. 10.1016/j.bbadis.2010.03.001
68
MascarenhasS.LeiteJ.GalvãoG.AlvesA. (2014). Effect of ouabain on NFκB and p-38 activation in macrophages: a new biotechnological application. BMC Proc.8 (Suppl. 4):P260. 10.1186/1753-6561-8-S4-P260
69
MasliS.TurpieB. (2008). Anti-inflammatory effects of tumour necrosis factor (TNF)-alpha are mediated via TNF-R2 (p75) in tolerogenic transforming growth factor-beta-treated antigen-presenting cells. Immunology127, 62–72. 10.1111/j.1365-2567.2008.02933.x
70
MasochaW.GonzálezL. G.AgilA. (2016). Distinguishing subgroups among μ-opioid receptor agonists using Na(+),K(+)-ATPase as an effector mechanism. Eur. J. Pharmacol.774, 43–49. 10.1016/j.ejphar.2016.01.010
71
MasochaW.HorvathG.AgilA.OcanaM.Del PozoE.SzikszayM.et al. (2003). Role of Na(+),K(+)-ATPase in morphine-induced antinociception. J. Pharmacol. Exp. Ther.306, 1122–1128. 10.1124/jpet.103.052977
72
MasugiF.OgiharaT.HasegawaT.SakaguchiK.KumaharaY. (1988). Normalization of high plasma level of ouabain-like immunoreactivity in primary aldosteronism after removal of adenoma. J. Hum. Hypertens. 2, 17–20.
73
MatsumoriA.OnoK.NishioR.IgataH.ShioiT.MatsuiS.et al. (1997). Modulation of cytokine production and protection against lethal endotoxemia by the cardiac glycoside ouabain. Circulation96, 1501–1506. 10.1161/01.CIR.96.5.1501
74
MatsumoriA.OnoK.NishioR.NoseY.SasayamaS. (2000). Amlodipine inhibits the production of cytokines induced by ouabain. Cytokine12, 294–297. 10.1006/cyto.1999.0555
75
MayadasT. N.CullereX.LowellC. A. (2014). The multifaceted functions of neutrophils. Annu. Rev. Pathol.9, 181–218. 10.1146/annurev-pathol-020712-164023
76
MedzhitovR. (2008). Origin and physiological roles of inflammation. Nature454, 428–435. 10.1038/nature07201
77
MedzhitovR. (2010). Inflammation 2010: new adventures of an old flame. Cell140, 771–776. 10.1016/j.cell.2010.03.006
78
NascimentoC. R.ValenteR. C.Echevarria-LimaJ.FontesC. F.de Araujo-MartinsL.AraujoE. G.et al. (2014). The influence of ouabain on human dendritic cells maturation. Med. Inflamm.2014, 4949–4956. 10.1155/2014/494956
79
NathanC. (2002). Points of control in inflammation. Nature420, 846–852. 10.1038/nature01320
80
NesherM.DvelaM.IgbokweV. U.RosenH.LichtsteinD. (2009). Physiological roles of endogenous ouabain in normal rats. Am. J. Physiol. Heart Circ. Physiol. 297, H2026–H2034. 10.1152/ajpheart.00734.2009
81
NinsontiaC.ChanvorachoteP. (2014). Ouabain mediates integrin switch in human lung cancer cells. Anticancer Res.34, 5495–5502.
82
OkazakiT.IleaV. S.OkazakiA.WicherK.ReismanR. E.ArbesmanC. E. (1976). Inhibition of antigen-induced histamine release by ouabain. J. Allergy Clin. Immunol.57, 454–462. 10.1016/0091-6749(76)90061-0
83
OlejB.de La RocqueL.CastilhoF. P.MedianoI. F.CamposM. M.RumjanekV. M. (1994). Effect of ouabain on lymphokine-activated killer cells. Int. J. Immunopharmacol.16, 769–774. 10.1016/0192-0561(94)90097-3
84
OlejB.dos SantosN. F.LealL.RumjanekV. M. (1998). Ouabain induces apoptosis on PHA-activated lymphocytes. Biosci. Rep.18, 1–7. 10.1023/A:1022259832207
85
OrellanaA. M.KinoshitaP. F.LeiteJ. A.KawamotoE. M.ScavoneC. (2016). Cardiotonic steroids as modulators of neuroinflammation. Front. Endocrinol.7:10. 10.3389/fendo.2016.00010
86
PadroC. J.SandersV. M. (2014). Neuroendocrine regulation of inflammation. Semin. Immunol.26, 357–368. 10.1016/j.smim.2014.01.003
87
PanayiotidisM. I.FrancoR.BortnerC. D.CidlowskiJ. A. (2010). Ouabain-induced perturbations in intracellular ionic homeostasis regulate death receptor-mediated apoptosis. Apoptosis15, 834–849. 10.1007/s10495-010-0494-8
88
ParkinJ.CohenB. (2001). An overview of the immune system. Lancet357, 1777–1789. 10.1016/S0140-6736(00)04904-7
89
PiresV.HarabR. C.OlejB.RumjanekV. M. (1997). Ouabain effects on activated lymphocytes: augmentation of CD25 expression on TPA-stimulated cells and of CD69 on PHA- and TPA-stimulated cells. Int. J. Immunopharmacol.19, 143–147. 10.1016/S0192-0561(96)00070-7
90
PongrakhananonV.ChunhachaP.ChanvorachoteP. (2013). Ouabain suppresses the migratory behavior of lung cancer cells. PLoS ONE8:e68623. 10.1371/journal.pone.0068623
91
ProcacciniC.PucinoV.De RosaV.MaroneG.MatareseG. (2014). Neuro-endocrine networks controlling immune system in health and disease. Front. Immunol.5:143. 10.3389/fimmu.2014.00143
92
QuastelM. R.KaplanJ. G. (1968). Inhibition by ouabain of human lymphocyte transformation induced by phytohaemagglutinin in vitro. Nature219, 198–200. 10.1038/219198a0
93
RayE.SamantaA. K. (1997). Receptor-mediated endocytosis of IL-8: a fluorescent microscopic evidence and implication of the process in ligand-induced biological response in human neutrophils. Cytokine9, 587–596. 10.1006/cyto.1997.0206
94
RedondoJ. M.López RivasA.FresnoM. (1986). Activation of the Na+/K+-ATPase by interleukin-2. FEBS Lett.206, 199–202. 10.1016/0014-5793(86)80980-2
95
Rodrigues-MascarenhasS.BloiseF. F.MoscatJ.RumjanekV. M. (2008). Ouabain inhibits p38 activation in thymocytes. Cell. Biol.32, 1323–1328. 10.1016/j.cellbi.2008.07.012
96
Rodrigues-MascarenhasS.Da Silva de OliveiraA.AmoedoN. D.Affonso-MitidieriO. R.RumjanekF. D.RumjanekV. M. (2009). Modulation of the immune system by ouabain. Ann. N. Y. Acad. Sci. 1153, 153–163. 10.1111/j.1749-6632.2008.03969.x
97
Rodrigues-MascarenhasS.dos SantosN. F.RumjanekV. M. (2006). Synergistic effect between ouabain and glucocorticoids for the induction of thymic atrophy. Biosci. Rep. 26, 159–169. 10.1007/s10540-006-9012-1
98
Rodrigues-MascarenhasS.Echevarria-LimaJ.Fernandes dos SantosN.RumjanekV. M. (2003). CD69 expression induced by thapsigargin, phorbol ester and ouabain on thymocytes is dependent on external Ca2+ entry. Life Sci.73, 1037–1051. 10.1016/S0024-3205(03)00377-1
99
RossiG.ManuntaP.HamlynJ. M.PavanE.De ToniR.SempliciniA.et al. (1995). Immunoreactive endogenous ouabain in primary aldosteronism and essential hypertension: relationship with plasma renin, aldosterone and blood pressure levels. J. Hypertens. 13, 1181–1191. 10.1097/00004872-199510000-00013
100
SaundersR.Scheiner-BobisG. (2004). Ouabain stimulates endothelin release and expression in human endothelial cells without inhibiting the sodium pump. Eur. J. Biochem.271, 1054–1062. 10.1111/j.1432-1033.2004.04012.x
101
SchellerJ.ChalarisA.Schmidt-ArrasD.Rose-JohnS. (2013).The pro- and anti-inflammatory properties of the cytokine interleukin-6. Biochim. Biophys. Acta1813, 878–888. 10.1016/j.bbamcr.2011.01.034
102
SchneiderR.WrayV.NimtzM.LehmannW. D.KirchU.AntolovicR.et al. (1998). Bovine adrenals contain, in addition to ouabain, a second inhibitor of the sodium pump. J. Biol. Chem.273, 784–792. 10.1074/jbc.273.2.784
103
SchonerW.Scheiner-BobisG. (2005). Endogenous cardiac glycosides: hormones using the sodium pump as signal transducer. Semin. Nephrol. 25, 343–351. 10.1016/j.semnephrol.2005.03.010
104
SchonerW. (2002). Endogenous cardiac glycosides, a new class of steroid hormones. Eur. J. Biochem. 269, 2440–2448. 10.1046/j.1432-1033.2002.02911.x
105
SchonerW.Scheiner-BobisG. (2007). Endogenous and exogenous cardiac glycosides and their mechanisms of action. Am. J. Cardiovasc. Drugs7, 173–189. 10.2165/00129784-200707030-00004
106
ScrivoR.VasileM.BartosiewiczI.ValesiniG. (2011). Inflammation as “common soil” of the multifactorial diseases. Autoimmun. Rev.10, 369–374. 10.1016/j.autrev.2010.12.006
107
SenolM.OzerolI. H.PatelA. V.SkonerD. P. (2007). The effect of Na+-K+ ATPase inhibition by ouabain on histamine release from human cutaneous mast cells. Mol. Cell. Biochem.294, 25–29. 10.1007/s11010-006-9180-0
108
SetiadyY. Y.CocciaJ. A.ParkP. U. (2010). In vivo depletion of CD4+FOXP3+ Treg cells by the PC61 anti-CD25 monoclonal antibody is mediated by FcgammaRIII+ phagocytes. Eur. J. Immunol.40, 780–786. 10.1002/eji.200939613
109
ShinH. K.RyuB. J.ChoiS.-W.KimS. H.LeeK. (2015). Inactivation of Src-to-ezrin pathway: a possible mechanism in the ouabain-mediated inhibition of A549 cell migration. Biomed. Res. Int.2015:537136. 10.1155/2015/537136
110
SilvaJ. M.Das Neves AzevedoA.Corrêa AleixoR.Mendes ClementeA.Ribeiro CabralV.PaivaL. S. (2015). Ouabain improves the response to melanoma (B16) in mice by modulating B and T lymphocytes. Front. Immunol. Conference Abstract: IMMUNOCOLOMBIA2015 - 11th Congress of the Latin American Association of Immunology - 10o. Congreso de la Asociación Colombiana de Alergia, Asma e Inmunología.
111
SmolyaninovaL. V.DergalevA. A.KulebyakinK. Y.CarpenterD. O.BoldyrevA. A. (2013). Carnosine prevents necrotic and apoptotic death of rat thymocytes via ouabain sensitive Na/K-ATPase. Cell Biochem. Funct.31, 30–35. 10.1002/cbf.2856
112
SoehnleinO.SteffensS.HidalgoA.WeberC. (2017). Neutrophils as protagonists and targets in chronic inflammation. Nat. Rev. Immunol.17, 248–261. 10.1038/nri.2017.10
113
SowaG.PrzewłockiR. (1997). Ouabain enhances the lipopolysaccharide-induced nitric oxide production by rat peritoneal macrophages. Immunopharmacol36, 95–100. 10.1016/S0162-3109(96)00159-2
114
SteinmanR. M. (2012). Decisions about dendritic cells: past, present, and future. Annu. Rev. Immunol. 30, 1–22. 10.1146/annurev-immunol-100311-102839
115
StellaP.ManuntaP.MallamaciF.MelandriM.SpottiD.TripepiG.et al. (2008). Endogenous ouabain and cardiomyopathy in dialysis patients. J. Intern Med.263, 274–280. 10.1111/j.1365-2796.2007.01883.x
116
SugimotoM. A.SousaL. P.PinhoV.PerrettiM.TeixeiraM. M. (2016). Resolution of inflammation: what controls its onset?Front. Immunol.7:160. 10.3389/fimmu.2016.00160
117
SzamelM.LeufgenH.KurrleR.ReschK. (1995). Differential signal transduction pathways regulating interleukin-2 synthesis and interleukin-2 receptor expression in stimulated human lymphocytes. Biochim. Biophys. Acta1235, 33–42. 10.1016/0005-2736(94)00297-3
118
TakadaY.MatsuoK.OguraH.BaiL.TokiA.WangL.et al. (2009). Odoroside A and ouabain inhibit Na+/K+-ATPase and prevent NF-kappaB inducible protein expression by blocking Na+-dependent amino acid transport. Biochem. Pharmacol. 78, 1157–1166. 10.1016/j.jpain.2007.07.006
119
TayalV.KalraB. S. (2008). Cytokines and anti-cytokines as therapeutics–an update. Eur. J. Pharmacol.579, 1–12. 10.1016/j.ejphar.2007.10.049
120
TeixeiraM. P.RumjanekV. M. (2014). Ouabain affects the expression of activation markers, cytokine production, and endocytosis of human monocytes. Med. Inflamm.2014, 7603–7668. 10.1155/2014/760368
121
ToninP. T.ValvassoriS. S.Lopes-BorgesJ.MariotE.VarelaR. B.TeixeiraA. L.et al. (2014). Effects of ouabain on cytokine/chemokine levels in an animal model of mania. J. Neuroimmunol.276, 236–239. 10.1016/j.jneuroim.2014.09.007
122
TymiakA. A.NormanJ. A.BolgarM.DiDonatoG. C.LeeH.ParkerW. L.et al. (1993). Physicochemical characterization of a ouabain isomer isolated from bovine hypothalamus. Proc Natl Acad Sci.U.S.A.90, 8189–8193. 10.1073/pnas.90.17.8189
123
ValenteR. C.NascimentoC. R.AraujoE. G.RumjanekV. M. (2009). mCD14 expression in human monocytes is downregulated by ouabain via transactivation of epithelial growth factor receptor and activation of p38 mitogen activated protein kinase. Neuroimmunomodulation16, 228–236. 10.1159/000212383
124
VestweberD. (2015). How leukocytes cross the vascular endothelium. Nat. Rev. Immunol.15, 692–704. 10.1038/nri3908
125
WangJ.AraseH. (2014). Regulation of immune responses by neutrophils. Ann. N. Y. Acad. Sci.1319, 66–81. 10.1111/nyas.12445
126
WangJ.VelottaJ. B.McDonoughA. A.FarleyR. A. (2001). All human Na(+)-K(+)-ATPase alpha-subunit isoforms have a similar affinity for cardiac glycosides. Am. J. Physiol. Cell Physiol.281, C1336–C1343.
127
WardP. A.BeckerE. L. (1970). Potassium reversible inhibition of leukotaxis by ouabain. Life Sci.9, 355–360. 10.1016/0024-3205(70)90180-3
128
XieZ.AskariA. (2002). Na+/K+-ATPase as a signal transducer. Eur. J. Biochem.269, 2434–2439. 10.1046/j.1432-1033.2002.02910.x
129
XieZ.CaiT. (2003). Na+-K+-ATPase-mediated signal transduction: from protein interaction to cellular function. Mol. Interv.3, 157–168. 10.1124/mi.3.3.157
130
ZakharovaM.ZieglerH. K. (2005). Paradoxical anti-inflammatory actions of TNF-alpha: inhibition of IL-12 and IL-23 via TNF receptor 1 in macrophages and dendritic cells. J. Immunol.175, 5024–5033. 10.4049/jimmunol.175.8.5024
131
ZengW.ChenX.DohiS. (2007). Antinociceptive synergistic interaction between clonidine and ouabain on thermal nociceptive tests in the rat. J. Pain8, 983–988. 10.1016/j.bcp.2009.06.027
132
ZengW.DohiS.ShimonakaH.AsanoT. (1999). Spinal antinociceptive action of Na+-K+ pump inhibitor ouabain and its interaction with morphine and lidocaine in rats. Anesthesiology90, 500–508. 10.1097/00000542-199902000-00026
Summary
Keywords
ouabain, immune system, peripheral inflammation, cell migration, cytokines, neuroinflammation
Citation
Cavalcante-Silva LHA, Lima ÉdA, Carvalho DCM, Sales-Neto JMd, Alves AKdA, Galvão JGFM, Silva JSdFd and Rodrigues-Mascarenhas S (2017) Much More than a Cardiotonic Steroid: Modulation of Inflammation by Ouabain. Front. Physiol. 8:895. doi: 10.3389/fphys.2017.00895
Received
06 September 2017
Accepted
24 October 2017
Published
10 November 2017
Volume
8 - 2017
Edited by
Carlos Rosales, Universidad Nacional Autónoma de México, Mexico
Reviewed by
Bruno Vogt, University of Bern, Switzerland; Timothy J. Moss, Ritchie Centre, Australia
Updates
Copyright
© 2017 Cavalcante-Silva, Lima, Carvalho, Sales-Neto, Alves, Galvão, Silva and Rodrigues-Mascarenhas.
This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
*Correspondence: Sandra Rodrigues-Mascarenhas sandra@cbiotec.ufpb.br
This article was submitted to Integrative Physiology, a section of the journal Frontiers in Physiology
Disclaimer
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.